Monika Warzecha

Dr. Monika Warzecha

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2017 in Crystal Growth & Design
Verified
Journal Article
Closed access
MWMonika Warzecha
Monika Warzecha
RGRui Guo
Rui Guo
RBRajni Miglani Bhardwaj
Rajni Miglani Bhardwaj
SRSusan M. Reutzel-Edens
Susan M. Reutzel-Edens
SPSarah L. Price
Sarah L. Price
AFAlastair J. Florence
Alastair J. Florence

7 November 2017 in Crystal Growth & Design
Verified
Journal Article
Closed access
MWMonika Warzecha
Monika Warzecha
MSMohammad S. Safari
Mohammad S. Safari
AFAlastair J. Florence
Alastair J. Florence
PVPeter Vekilov
Peter Vekilov

1 January 2018 in Drug Delivery
Verified
Journal Article
Open access
NANajla Altwaijry
Najla Altwaijry
SSSukrut Somani
Sukrut Somani
JPJohn Andrew Parkinson
John Andrew Parkinson
RTRothwelle J. Tate
Rothwelle J. Tate
PKPatricia Keating
Patricia Keating
Christine DufèsChristine Dufès
Christine Dufès
The possibility of using gene therapy for the treatment of prostate cancer is limited by the lack of intravenously administered delivery systems able to safely and selectively deliver therapeutic genes to tumors. Given that lactoferrin (Lf) receptors are overexpressed on prostate cancer cells, we hypothesized that the conjugation of Lf to generation 3-diaminobutyric polypropylenimine dendrimer would improve its transfection and therapeutic efficacy in prostate cancer cells. In this study, we demonstrated that the intravenous administration of Lf-bearing DAB dendriplexes encoding TNFα resulted in the complete suppression of 70% of PC-3 and 50% of DU145 tumors over one month. Treatment with DAB-Lf dendriplex encoding TRAIL led to tumor suppression of 40% of PC-3 tumors and 20% of DU145 tumors. The treatment was well tolerated by the animals. Lf-bearing generation 3-polypropylenimine dendrimer is therefore a highly promising delivery system for non-viral gene therapy of prostate cancer.

23 September 2020 in Nature Chemistry
Verified
Journal Article
Closed access
PDF file
MWMonika Warzecha
Monika Warzecha
LVLakshmanji Verma
Lakshmanji Verma
BJBlair F. Johnston
Blair F. Johnston
JPJeremy C. Palmer
Jeremy C. Palmer
AFAlastair J. Florence
Alastair J. Florence
PVPeter Vekilov
Peter Vekilov

6 November 2018 in Nanoscale
Verified
Journal Article
Closed access
PDF file
Partha LaskarPartha Laskar
Partha Laskar
SSSukrut Somani
Sukrut Somani
NANajla Altwaijry
Najla Altwaijry
MMMargaret Mullin
Margaret Mullin
DBDeborah Bowering
Deborah Bowering
Christine DufèsChristine Dufès
Christine Dufès
Stimuli-responsive nanocarriers have attracted increased attention as materials that can facilitate drug and gene delivery in cancer therapy. The present study reports the development of redox-sensitive dendrimersomes comprising disulfide-linked cholesterol-bearing PEGylated dendrimers, which can be used as drug and gene delivery systems. Two disulfide-linked cholesterol-bearing PEGylated generation 3 diaminobutyric polypropylenimine dendrimers have been successfully synthesized via an in situ two-step reaction. They were able to spontaneously self-assemble into stable, cationic, nanosized vesicles (or dendrimersomes) with lower critical aggregation concentration values for high-cholesterol-bearing vesicles. These dendrimersomes were able to entrap both hydrophilic and hydrophobic dyes, and they also showed a redox-responsive sustained release of the entrapped guests in the presence of a glutathione concentration similar to that of a cytosolic reducing environment. The high-cholesterol-bearing dendrimersomes were found to have a higher melting enthalpy, increased adsorption tendency on mica surface, entrapping ability for a larger amount of hydrophobic drugs, and increased resistance to redox-responsive environments in comparison with their low-cholesterol counterpart. In addition, both dendrimersomes were able to condense more than 85% of the DNA at all the tested ratios for the low-cholesterol vesicles, and at dendrimer : DNA weight ratios of 1 : 1 and higher for the high-cholesterol vesicles. These vesicles resulted in an enhanced cellular uptake of DNA, by up to 15-fold when compared with naked DNA with low-cholesterol vesicles. As a result, they increased the gene transfection on the PC-3 prostate cancer cell line, with the highest transfection being obtained with low-cholesterol vesicle complexes at a dendrimer : DNA weight ratio of 5 : 1 and high-cholesterol vesicle complexes at a dendrimer : DNA weight ratio of 10 : 1. These transfection levels were about 5-fold higher than those observed when treated with naked DNA. These cholesterol-bearing PEGylated dendrimer-based vesicles are, therefore, promising as redox-sensitive drugs and gene delivery systems for potential applications in combination cancer therapies.

21 January 2015 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
MWMonika Warzecha
Monika Warzecha
MOM. Oszajca
M. Oszajca
KPKacper Pilarczyk
Kacper Pilarczyk
KSKonrad Szaciłowski
Konrad Szaciłowski
A new application of a hybrid material exhibiting the photoelectrochemical photocurrent switching (peps) effect in a three-valued logic device is reported. In contrast to other similar peps-based systems, the one described here is capable of performing basic ternary logic operations: gullibility and consensus.